Table 1. Quantification of tumor accumulation of different liposome formulations as determined by whole mouse fluorescent imaging.
| Liposome Formulation |
Radiant Efficiency (x 109)
|
|||
|---|---|---|---|---|
| 24hrs | 48hrs | 72hrs | ||
| H2009 tumors | H2009.1 Tetrameric | 10.1 ± 0.0922 | 10.2 ± 0.601 | 12.2 ± 0.452 |
| AcH2009.1 Tetrameric | 5.96 ± 1.86 | 5.36 ± 1.91 | 5.96 ± 1.59 | |
| scH2009.1 Tetrameric | 9.91 ± 1.37 | 12.1 ± 0.676 | 12.8 ± 1.03 | |
| Naked | 9.41 ± 1.65 | 11.3 ± 1.54 | 13.3 ± 2.32 | |
| H460 tumors | H2009.1 Tetrameric | 12.4 ± 1.90 | 12.8 ± 1.80 | 12.6 ± 1.39 |
| AcH2009.1 Tetrameric | 5.30 ± 0.529 | 4.95 ± 0.327 | 5.08 ± 0.373 | |
| scH2009.1 Tetrameric | 12.3 ± 3.01 | 14.1 ± 4.68 | 14.9 ± 3.77 | |
| Naked | 8.26 ± 1.20 | 11.3 ± 1.65 | 11.2 ± 0.840 | |
Quantification of the tumor accumulation of DiR-labeled liposomes in either αvβ6-positive H2009 or αvβ6-negative H460 tumors at different time points post-liposome injection, as visualized by whole mouse fluorescent imaging in Figure 3.